2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1142

Joint Specific Function of Synovial Fibroblasts – Integrating Positional Transcriptomes and Anatomic Patterns of Arthritis

Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

9:00AM-11:00AM: Abstract Number: 1838

Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1473

Juvenile Psoriatic Arthritis Manifestations in a Cohort of 361 Patients from US and Canada

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1455

Juvenile Spondyloarthropathies: a Single Center Experience

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1202

Knowledge and Perception of Cardiovascular Disease Risk in Patients with Psoriatic Disease

Education Poster (ARHP): Education/Community Programs

9:00AM-11:00AM: Abstract Number: 1135

Krüppel-like Factors (Klfs), Novel Transcriptional Regulators of Articular Chondrocytes That Are Abnormally Expressed in Osteoarthritic Cartilage

Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

9:00AM-11:00AM: Abstract Number: 1609

Lack of Association Between ZHX2, Lepr, Gckr and ASCL1 and Carotid Intima-Media Thickness, Carotid Plaques and Cardiovascular Disease in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1952

Lack of Association of a 6.7 Kbp Deletion of LILRA3 with Giant Cell Arteritis

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1659

Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1615

Lack of Replication of the Association Between Anti-Citrullinated Fibrinogen and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1991

Large Vessel Involvement By IgG4-Related Disease

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1821

Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1508

Lipid Target Achievement Among Patients with Recent-Onset Rheumatoid Arthritis during the First Six Years of Follow-up: Results from a French Multicenter Cohort of Early Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1788

Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1396

Long Term Outcome of Neurosarcoidosis

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].